Analysts Offer Insights on Healthcare Companies: Xilio Therapeutics (XLO) and Neurocrine (NBIX)
TipRanksNov 10, 2023 07:52
Promising Clinical Trials and Potential Therapies Propel Buy Rating for Xilio Therapeutics
TipRanksNov 7, 2023 19:26
Chardan Capital Sticks to Its Buy Rating for Xilio Therapeutics (XLO)
TipRanksMay 30, 2023 20:35
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target
BenzingaMay 30, 2023 17:17
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target
BenzingaMay 11, 2023 16:47
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating
MT NewswiresJan 28, 2023 00:56
Xilio Therapeutics Analyst Ratings
Benzinga Analyst RatingsJan 27, 2023 23:49
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10
Benzinga Real-time NewsJan 27, 2023 23:48
Xilio Therapeutics Analyst Ratings
Benzinga Analyst RatingsDec 21, 2022 19:26
Raymond James Adjusts Price Target on Xilio Therapeutics to $13 From $31, Maintains Outperform Rating
MT NewswiresNov 10, 2022 23:21
Xilio Therapeutics Analyst Ratings
Benzinga Analyst RatingsNov 10, 2022 17:46
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $13
Benzinga Real-time NewsNov 10, 2022 17:26
No Data
No Data